A detailed history of Putnam Investments LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Putnam Investments LLC holds 70,067 shares of MGNX stock, worth $304,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,067
Previous 42,083 66.5%
Holding current value
$304,791
Previous $196,000 243.88%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $125,368 - $282,918
27,984 Added 66.5%
70,067 $674,000
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $188,531 - $260,493
42,083 New
42,083 $196,000
Q2 2022

Aug 15, 2022

SELL
$2.25 - $9.99 $114,077 - $506,502
-50,701 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$8.12 - $16.9 $108,661 - $226,155
13,382 Added 35.86%
50,701 $446,000
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $593,745 - $816,539
37,319 New
37,319 $599,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $267M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Putnam Investments LLC Portfolio

Follow Putnam Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.